Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575712 | 0.95 | PTGES (0.64) | PTGESCHRNA7ALDH1A1KMT2AMAPT | |
| SCHEMBL3578959 | 0.88 | PTGES (0.77) | PTGESKMT2AMAPT | |
| SCHEMBL3574862 | 0.86 | PTGES (0.77) | PTGESMCHR1ALDH1A1KMT2AKDM4E | |
| SCHEMBL3574312 | 0.85 | PTGES (0.53) | PTGESMCHR1ALDH1A1MAPTIDO1 | |
| SCHEMBL3577515 | 0.85 | PTGES (0.53) | PTGESMAPTIDO1 | |
| SCHEMBL3001458 | 0.84 | PTGES (0.51) | PTGESMAPK1ALDH1A1KMT2AMAPT | |
| SCHEMBL3577805 | 0.84 | PTGES (0.53) | PTGESALDH1A1FAAHMAPTLMNA | |
| SCHEMBL4224238 | 0.83 | PTGES (0.45) | PTGESMAPK1GABRA2GABRB2NOD2 | |
| SCHEMBL2997482 | 0.83 | PTGES (0.50) | PTGESALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL3578734 | 0.83 | PTGES (0.50) | PTGESALDH1A1KMT2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705023-B2 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2010-04-27 | — | — | US | disclosed |
| EP-1778632-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2007-12-13 | — | — | US | disclosed |
| EP-1778632-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2005123673-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | PTGS1, IDO1, PTGES | PTGES 3/4885MAPK1 1991/4885GABRA2 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.